Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential

被引:121
作者
Colucci, Marie A. [1 ]
Moody, Christopher J. [1 ]
Couch, Gavin D. [1 ]
机构
[1] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England
关键词
D O I
10.1039/b715270a
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The quinone reductase enzyme NAD(P)H: quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes the two-electron reduction of quinones. This Perspective briefly reviews the structure and mechanism, physiological role, and upregulation and induction of the enzyme, but focuses on the synthesis of new heterocyclic quinones and their metabolism by recombinant human NQO1. Thus a range of indolequinones, some of which are novel analogues of mitomycin C, benzimidazolequinones, benzothiazolequinones and quinolinequinones have been prepared and evaluated, leading to detailed knowledge of the structural requirements for efficient metabolism by the enzyme. Potent mechanism-based inhibitors (suicide substrates) of NQO1 have also been developed. These indolequinones irreversibly alkylate the protein, preventing its function both in standard enzyme assays and also in cells. Some of these quinones are also potent inhibitors of growth of human pancreatic cancer cells, suggesting a potential role for such compounds as therapeutic agents.
引用
收藏
页码:637 / 656
页数:20
相关论文
共 99 条
[1]   NQO1-directed antitumour quinones [J].
Alcain, Francisco J. ;
Villalba, Jose M. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (06) :649-665
[2]  
[Anonymous], ENZYME PRODRUG STRAT
[3]  
Asher G, 2004, METHOD ENZYMOL, V382, P278
[4]   The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol [J].
Asher, Gad ;
Dym, Orly ;
Tsvetkov, Peter ;
Adler, Julia ;
Shaul, Yosef .
BIOCHEMISTRY, 2006, 45 (20) :6372-6378
[5]   Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1 [J].
Beall, HD ;
Hudnott, AR ;
Winski, S ;
Siegel, D ;
Swann, E ;
Ross, D ;
Moody, CJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (05) :545-548
[6]   Mechanisms of action of quinone-containing alkylating agents I: NQO1-directed drug development [J].
Beall, HD ;
Winski, SL .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :D639-D648
[7]   Indolequinone antitumor agents:: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity [J].
Beall, HD ;
Winski, S ;
Swann, E ;
Hudnott, AR ;
Cotterill, AS ;
O'Sullivan, N ;
Green, SJ ;
Bien, R ;
Siegel, D ;
Ross, D ;
Moody, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4755-4766
[8]   Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin [J].
Beall, HD ;
Liu, YF ;
Siegel, D ;
Bolton, EM ;
Gibson, NW ;
Ross, D .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (05) :645-652
[9]  
Begleiter A, 2004, METHOD ENZYMOL, V382, P320
[10]  
Bianchet MA, 2004, METHOD ENZYMOL, V382, P144